Press Release

Human Insulin Market 2019 Movements by Growth Status, Revenue Expectation to 2026 | Research Report by Fortune Business Insights

Human Insulin Market Advances with Introduction of Technologies in Insulin Delivery: Fortune Business Insights

The growing prevalence of diabetes across the world is prophesied to expand the global human insulin market. The above information was provided by Fortune Business Insights in a report, titled “Human Insulin Market Size, Share and Global Trend by Drug Type (Biologics, Biosimilar), By Delivery Devices (Vials & Syringes, Insulin Pens, Insulin Pumps), By Type of Patients (Type 1 diabetes, Type 2 diabetes), By Mode of Action (Long-Acting, Rapid-Acting, Short-Acting, Intermediate-Acting, Premix Insulin), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography Forecast till 2026.” These numbers are primarily increasing on account of growing obesity rates. The International Diabetes Foundation (IDF) estimates the prevalence of diabetes to grow in the coming years. The number of diabetic patients registered in 2017 were 425 Million and is projected to reach 629 Million by 2045.

Request Sample [email protected] https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/human-insulin-market-100395

Top Key Players Covered:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the Human Insulin Market. Some of the companies operating the global market are;

  • GlaxoSmithKline plc.
  • Novartis AG
  • Omron Healthcare, Inc.
  • PARI
  • Philips Respironics, Inc.
  • 3M
  • Sunovion Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH

Browse Complete Report [email protected] https://www.fortunebusinessinsights.com/industry-reports/human-insulin-market-100395

Market Advances with Rapid Improvements in Insulin Delivery in North America

Among regions, North America is anticipated to dominate the global human insulin market during the forecast period. The growth is majorly witnessed on account of the rising prevalence of diabetes and its related disorders. Furthermore, the demand for human infusion insulin devices is increasing owing to their availability and technological improvements.  On the other hand, the market in Asia Pacific is likely to witness high growth between 2018 and 2026. The rising research and development (R&D) investments and presence of well-known manufacturing companies in this region are creating ample growth opportunities for the market. These companies are likely to boost the human insulin market in the upcoming years.

SEGMENTATION 

By Drug Type

  • Biologics
  • Biosimilars

By Delivery Devices

  • Vials & Syringes
  • Insulin Pens
  • Insulin Pumps
  • Others

By Type of Patients

  • Type 1 diabetes
  • Type 2 diabetes

By Mode of Action

  • Long-Acting
  • Rapid-Acting
  • Short-Acting
  • Intermediate-Acting
  • Premix Insulin

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America (USA and Canada)
  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Sanofi’s Launch of Admelog Intends to Improve Blood Sugar Levels in Patients

Some of the leading players operating in the global human insulin market include Novo Nordisk, Sanofi A/S, Eli Lilly & Company, Astra Zeneca plc, GlaxoSmithKline plc, Tonghua Dongbao Pharmaceutical Co., Biocon, Julphar, and Wockhardt. Sebveral compaies are planning to focus on collaborations and partnerships to gain market share. For instance, Ypsomed AG partnered with with Koninklijke Philips N.V. in October 2018. The aim of this collaboration was to conjointly develop and deploy novel self-medication monitoring services. In November 2018, Biocon and Mylan announced the launch of a new biosimilar called Semglee. The drug is indicated to treat patients suffering from diabetes mellitus in adults and children. Companies are also focussing to launch new products to stay industry focussed. For instance, Sanofi launched an insulin lispro product called Admelog in April 2018. This product is intended to control insulin levels in children and adults.

More Trending Topics From Fortune Business [email protected]

Mycotoxin Detoxifiers Market 2019 Top Leading Players, Emerging Trends, Global Research, Region by Forecast to 2026

Revenue Cycle Management Market 2019: Global Industry Overview By Size, Share, for Rapid Growth by 2025

Surgical Staples Market: 2019 Global Industry Trends, Size and 2026 Forecast Research Report.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close